In a Phase I clinical trial evaluating the efficacy of IMP321 in combination with MART-1 for the treatment of patients with stage IV melanoma who received PBMC transplantation, the study revealed that while the overall response rate (ORR) was only 17%, IMP321 significantly stimulated CD8+ T cells to secrete higher levels of IFN-γ, TNF-α, and IL-2, indicating a more durable anti-tumor immune response (68). The gene discussed is CD8A; the disease is neoplasm.